The randomization code was broken at the site in 3 cases in the atorvastatin arm (due to liver cysts with elevated ALT level, acute hepatitis, and abnormal findings on liver function tests) and 2 cases in the placebo arm (due to high grade lymphoma and chest infection), none of which was attributed to trial medication. This evidence concerns the gene GPT and lymphoma.